Intervention Review

You have free access to this content

Megestrol acetate for treatment of anorexia-cachexia syndrome

  1. Vicente Ruiz Garcia1,*,
  2. Eduardo López-Briz2,
  3. Rafael Carbonell Sanchis3,
  4. Jose Luis Gonzalvez Perales4,
  5. Sylvia Bort-Marti5

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 28 MAR 2013

Assessed as up-to-date: 31 AUG 2012

DOI: 10.1002/14651858.CD004310.pub3


How to Cite

Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD004310. DOI: 10.1002/14651858.CD004310.pub3.

Author Information

  1. 1

    La Fe University Hospital, Hospital at Home Unit, Tower C, Floor 1 Office 5 & CASPe Spain, Valencia, Spain

  2. 2

    La Fe University Hospital, Department of Pharmacy & CASP Spain, Valencia, Valencia, Spain

  3. 3

    Sagunt Hospital, ENT Department, Sagunt, Valencia, Spain

  4. 4

    National Health Service, Algemesi, Valencia, Spain

  5. 5

    Acella Incubator, Paterna, Spain

*Vicente Ruiz Garcia, Hospital at Home Unit, Tower C, Floor 1 Office 5 & CASPe Spain, La Fe University Hospital, Av Fernando Abril Martorell nº 106, Valencia, 46026, Spain. vicenteruizgarcia@gmail.com.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 28 MAR 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias
[Figure 3]
Figure 3.
[Figure 4]
Figure 4.
[Figure 5]
Figure 5.
[Figure 6]
Figure 6.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 1 Appetite improvement.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 2 Appetite gain.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 3 Weight improvement.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 4 Weight gain.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 5 Quality of life improvement.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Megestrol acetate versus placebo (ITT), Outcome 6 Quality of life gain.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 1 Appetite improvement.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 2 Appetite gain.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 3 Weight improvement.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 4 Weight gain.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 5 Quality of life improvement.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Megestrol acetate versus other drugs (ITT), Outcome 6 Quality of life gain.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 1 Appetite improvement.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 2 Weight improvement.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 3 Weight improvement 160 mg versus other higher doses.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 4 Weight gain.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 5 Quality of life improvement.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Megestrol acetate versus megestrol acetate (ITT), Outcome 6 Quality of life gain.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Safety, Outcome 1 Acute decompensation of COPD or pulmonary exacerbation.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Safety, Outcome 2 Serious adverse events (SAE).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Safety, Outcome 3 Any adverse event.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Safety, Outcome 4 Abdominal pain.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Safety, Outcome 5 Abnormal appetite.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Safety, Outcome 6 Amenorrhoea/irregular menses.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Safety, Outcome 7 Bowel obstruction.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Safety, Outcome 8 Constipation.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Safety, Outcome 9 Chest pain.
[Analysis 4.10]
Analysis 4.10. Comparison 4 Safety, Outcome 10 Confusion.
[Analysis 4.11]
Analysis 4.11. Comparison 4 Safety, Outcome 11 Dyspnoea.
[Analysis 4.12]
Analysis 4.12. Comparison 4 Safety, Outcome 12 Depression.
[Analysis 4.13]
Analysis 4.13. Comparison 4 Safety, Outcome 13 Deaths.
[Analysis 4.14]
Analysis 4.14. Comparison 4 Safety, Outcome 14 Diarrhoea.
[Analysis 4.15]
Analysis 4.15. Comparison 4 Safety, Outcome 15 Drowsiness.
[Analysis 4.16]
Analysis 4.16. Comparison 4 Safety, Outcome 16 Elevated transaminase levels.
[Analysis 4.17]
Analysis 4.17. Comparison 4 Safety, Outcome 17 Glucose intolerance.
[Analysis 4.18]
Analysis 4.18. Comparison 4 Safety, Outcome 18 Hallucinations/psychosis.
[Analysis 4.19]
Analysis 4.19. Comparison 4 Safety, Outcome 19 Headaches.
[Analysis 4.20]
Analysis 4.20. Comparison 4 Safety, Outcome 20 Hyperphagia.
[Analysis 4.21]
Analysis 4.21. Comparison 4 Safety, Outcome 21 Heart burn.
[Analysis 4.22]
Analysis 4.22. Comparison 4 Safety, Outcome 22 Heart failure.
[Analysis 4.23]
Analysis 4.23. Comparison 4 Safety, Outcome 23 Hypertension.
[Analysis 4.24]
Analysis 4.24. Comparison 4 Safety, Outcome 24 Impotence.
[Analysis 4.25]
Analysis 4.25. Comparison 4 Safety, Outcome 25 Infections.
[Analysis 4.26]
Analysis 4.26. Comparison 4 Safety, Outcome 26 Inappropriate behaviour.
[Analysis 4.27]
Analysis 4.27. Comparison 4 Safety, Outcome 27 Insomnia.
[Analysis 4.28]
Analysis 4.28. Comparison 4 Safety, Outcome 28 Loss of co-ordination.
[Analysis 4.29]
Analysis 4.29. Comparison 4 Safety, Outcome 29 Nausea/vomiting.
[Analysis 4.30]
Analysis 4.30. Comparison 4 Safety, Outcome 30 Neoplasma.
[Analysis 4.31]
Analysis 4.31. Comparison 4 Safety, Outcome 31 Oedema.
[Analysis 4.32]
Analysis 4.32. Comparison 4 Safety, Outcome 32 Pneumonia.
[Analysis 4.33]
Analysis 4.33. Comparison 4 Safety, Outcome 33 Pruritus.
[Analysis 4.34]
Analysis 4.34. Comparison 4 Safety, Outcome 34 Pyrosis.
[Analysis 4.35]
Analysis 4.35. Comparison 4 Safety, Outcome 35 Pulmonary embolism.
[Analysis 4.36]
Analysis 4.36. Comparison 4 Safety, Outcome 36 Respiratory failure.
[Analysis 4.37]
Analysis 4.37. Comparison 4 Safety, Outcome 37 Other adverse events.
[Analysis 4.38]
Analysis 4.38. Comparison 4 Safety, Outcome 38 Skin disorder (includes vesiculobullous rash).
[Analysis 4.39]
Analysis 4.39. Comparison 4 Safety, Outcome 39 Sweating.
[Analysis 4.40]
Analysis 4.40. Comparison 4 Safety, Outcome 40 Swelling legs or abdominal.
[Analysis 4.41]
Analysis 4.41. Comparison 4 Safety, Outcome 41 Stroke.
[Analysis 4.42]
Analysis 4.42. Comparison 4 Safety, Outcome 42 Thromboembolic phenomena including thrombophlebitis.
[Analysis 4.43]
Analysis 4.43. Comparison 4 Safety, Outcome 43 Testicular shrinkage.
[Analysis 4.44]
Analysis 4.44. Comparison 4 Safety, Outcome 44 Withdrawals.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Sensitivity analyses, Outcome 1 Appetite improvement treatment duration 6 weeks.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Sensitivity analyses, Outcome 2 Appetite improvement treatment duration 12 weeks.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Sensitivity analyses, Outcome 3 Appetite gain 12 weeks.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Sensitivity analyses, Outcome 4 Weight improvement treatment duration 6 weeks.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Sensitivity analyses, Outcome 5 Quality of life gain.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Sensitivity analyses, Outcome 6 Weight improvement 12 weeks.
[Analysis 5.7]
Analysis 5.7. Comparison 5 Sensitivity analyses, Outcome 7 Weight gain 6 weeks.
[Analysis 5.8]
Analysis 5.8. Comparison 5 Sensitivity analyses, Outcome 8 Weight gain 12 weeks.
[Analysis 5.9]
Analysis 5.9. Comparison 5 Sensitivity analyses, Outcome 9 Blinded versus open-label appetite improvement.
[Analysis 5.10]
Analysis 5.10. Comparison 5 Sensitivity analyses, Outcome 10 Blinded versus open-label appetite gain.
[Analysis 5.11]
Analysis 5.11. Comparison 5 Sensitivity analyses, Outcome 11 Blinded versus open-label weight Improvement.
[Analysis 5.12]
Analysis 5.12. Comparison 5 Sensitivity analyses, Outcome 12 Sensitivity number patients weight improvement.
[Analysis 5.13]
Analysis 5.13. Comparison 5 Sensitivity analyses, Outcome 13 Appetite improvement, study quality.
[Analysis 5.14]
Analysis 5.14. Comparison 5 Sensitivity analyses, Outcome 14 Weight improvement, study quality.
[Analysis 5.15]
Analysis 5.15. Comparison 5 Sensitivity analyses, Outcome 15 Weight gain, study quality.
[Analysis 5.16]
Analysis 5.16. Comparison 5 Sensitivity analyses, Outcome 16 Sensitivity duration oedema.
[Analysis 5.17]
Analysis 5.17. Comparison 5 Sensitivity analyses, Outcome 17 Sensitivity duration thromboembolic phenomena.
[Analysis 5.18]
Analysis 5.18. Comparison 5 Sensitivity analyses, Outcome 18 Sensitivity blinded versus open-label weight gain.
[Analysis 5.19]
Analysis 5.19. Comparison 5 Sensitivity analyses, Outcome 19 Sensitivity number of patients in trial appetite improvement.
[Analysis 5.20]
Analysis 5.20. Comparison 5 Sensitivity analyses, Outcome 20 Sensitivity number of patients weight gain.
[Analysis 5.21]
Analysis 5.21. Comparison 5 Sensitivity analyses, Outcome 21 Sensitivity appetite improvement cancer.
[Analysis 5.22]
Analysis 5.22. Comparison 5 Sensitivity analyses, Outcome 22 Appetite improvement doses.
[Analysis 5.23]
Analysis 5.23. Comparison 5 Sensitivity analyses, Outcome 23 Weight improvement doses.
[Analysis 5.24]
Analysis 5.24. Comparison 5 Sensitivity analyses, Outcome 24 Sensitivity (cancer/other patients) thromboembolic phenomena.
[Analysis 5.25]
Analysis 5.25. Comparison 5 Sensitivity analyses, Outcome 25 Deaths sensitivity 6 weeks.
[Analysis 5.26]
Analysis 5.26. Comparison 5 Sensitivity analyses, Outcome 26 Deaths sensitivity/pathology.